$CELZ
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. Stock $celz

$celz Overview Financials Valuation SEC Filings Company Website

2018 Q1 Form 10-K Financial Statement

#000114420418017967 Filed on March 29, 2018

Income Statement

Concept	2018 Q1	2017	2016 Q4
Revenue	$9.600K	$4.800K	$0.00
YoY Change
Cost Of Revenue	$2.400K	$8.000K
YoY Change
Gross Profit	$7.200K	-$3.200K
YoY Change
Gross Profit Margin	75.0%	-66.67%
Selling, General & Admin	$200.0K	$898.5K	$170.0K
YoY Change	11.11%	35.12%	1600.0%
% of Gross Profit	2777.78%
Research & Development	$3.200K	$260.1K	$20.00K
YoY Change	-94.65%	204.78%
% of Gross Profit	44.44%
Depreciation & Amortization	$10.00K	$16.00K	$0.00
YoY Change		70.94%
% of Gross Profit	138.89%
Operating Expenses	$211.4K	$1.175M	$190.0K
YoY Change	-12.22%	54.62%	37900.0%
Operating Profit	-$204.2K	-$1.178M
YoY Change	-15.21%	55.04%
Interest Expense	$191.3K	$377.6K	$0.00
YoY Change	7537.05%	5801.64%
% of Operating Profit
Other Income/Expense, Net	-$7.382M	-$1.481M
YoY Change	294605.15%	23052.58%
Pretax Income	-$7.587M	-$2.659M	-$190.0K
YoY Change	3017.55%	247.11%	1800.0%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$7.587M	-$2.659M	-$190.0K
YoY Change	3017.55%	247.11%	37900.0%
Net Earnings / Revenue	-79026.88%	-55398.08%
Basic Earnings Per Share
Diluted Earnings Per Share	-$30.23K	-$1.873B	-$1.409K
COMMON SHARES
Basic Shares Outstanding	244.8M shares		102.1M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2018 Q1	2017	2016 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$100.0K	$13.70K	$220.0K
YoY Change	0.0%	-93.83%
Cash & Equivalents	$102.3K		$221.9K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables	$9.600K	$4.800K	$0.00
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$111.9K	$18.50K	$221.9K
YoY Change	14.06%	-91.66%	347.31%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$178.1K	$184.7K	$100.6K
YoY Change	81.71%	83.48%
TOTAL ASSETS
Total Short-Term Assets	$111.9K	$18.50K	$221.9K
Total Long-Term Assets	$178.1K	$184.7K	$100.6K
Total Assets	$290.0K	$203.2K	$322.5K
YoY Change	47.86%	-37.01%	550.23%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$230.0K	$237.6K	$66.39K
YoY Change	137.41%	257.84%
Accrued Expenses	$30.00K	$23.14K	$4.879K
YoY Change	335.35%	374.18%
Deferred Revenue
YoY Change
Short-Term Debt	$250.0K	$250.0K	$100.0K
YoY Change	150.0%	150.0%
Long-Term Debt Due	$260.0K	$251.7K
YoY Change
Total Short-Term Liabilities	$8.220M	$2.435M	$453.9K
YoY Change	1653.15%	436.55%	453764.0%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$920.00	$30.00K
YoY Change	-100.0%	-96.32%
Other Long-Term Liabilities	$0.00	$3.210K	$0.00
YoY Change		122.92%
Total Long-Term Liabilities	$0.00	$4.130K	$30.00K
YoY Change	-100.0%	-84.38%
TOTAL LIABILITIES
Total Short-Term Liabilities	$8.220M	$2.435M	$453.9K
Total Long-Term Liabilities	$0.00	$4.130K	$30.00K
Total Liabilities	$8.230M	$2.439M	$480.3K
YoY Change	1559.94%	407.87%	480203.0%
SHAREHOLDERS EQUITY
Retained Earnings			-$766.6K
YoY Change			153214.4%
Common Stock			$608.8K
YoY Change			1117.56%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$7.934M	-$2.236M	-$157.8K
YoY Change
Total Liabilities & Shareholders Equity	$290.0K	$203.2K	$322.5K
YoY Change	47.86%	-37.01%	550.23%

Cashflow Statement

Concept	2018 Q1	2017	2016 Q4
OPERATING ACTIVITIES
Net Income	-$7.587M	-$2.659M	-$190.0K
YoY Change	3017.55%	247.11%	37900.0%
Depreciation, Depletion And Amortization	$10.00K	$16.00K	$0.00
YoY Change		70.94%
Cash From Operating Activities	-$164.9K	-$889.6K	-$190.0K
YoY Change	-26.28%	99.81%
INVESTING ACTIVITIES
Capital Expenditures		$0.00	$0.00
YoY Change		-100.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00
YoY Change
Cash From Investing Activities	$0.00	$0.00	$0.00
YoY Change		-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$100.0K
YoY Change		-80.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	253.6K	681.5K	380.0K
YoY Change	153.55%	0.66%
NET CHANGE
Cash From Operating Activities	-164.9K	-889.6K	-190.0K
Cash From Investing Activities	0.000	$0.00	0.000
Cash From Financing Activities	253.6K	681.5K	380.0K
Net Change In Cash	88.61K	-208.2K	190.0K
YoY Change	-171.61%	-193.87%
FREE CASH FLOW
Cash From Operating Activities	-$164.9K	-$889.6K	-$190.0K
Capital Expenditures		$0.00	$0.00
Free Cash Flow		-$889.6K	-$190.0K
YoY Change		104.4%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017	dei	Entity Central Index Key EntityCentralIndexKey	0001187953
CY2017	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2017	dei	Document Type DocumentType	10-K
CY2017	dei	Amendment Flag AmendmentFlag	false
CY2017	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	15995	USD
CY2017	dei	Document Period End Date DocumentPeriodEndDate	2017-12-31
CY2017	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
CY2017	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2017	dei	Entity Registrant Name EntityRegistrantName	CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.
CY2017	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2017	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2017	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2017	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2017Q2	dei	Entity Public Float EntityPublicFloat	5665416	USD
CY2017	dei	Trading Symbol TradingSymbol	CELZ
CY2016Q4	us-gaap	Cash Cash	221868	USD
CY2016	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	94006533	shares
CY2016	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.01
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	221868	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	100	USD
CY2016	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	USD
CY2018Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	244815395	shares
CY2017Q4	us-gaap	Cash Cash	13697	USD
CY2017Q4	us-gaap	Assets Assets	203147	USD
CY2016Q4	us-gaap	Assets Assets	322512	USD
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	237566	USD
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	66385	USD
CY2017Q4	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	125000	USD
CY2016Q4	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	100000	USD
CY2017Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	23140	USD
CY2016Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4879	USD
CY2017Q4	us-gaap	Management Fee Payable ManagementFeePayable	352750	USD
CY2016Q4	us-gaap	Management Fee Payable ManagementFeePayable	280000	USD
CY2017Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2016Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	114800	USD
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	105014	USD
CY2017Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1074707	USD
CY2016Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	503767	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-3425680	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-766572	USD
CY2017Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-2236173	USD
CY2016Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-157791	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	203147	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	322512	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2435194	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	453864	USD
CY2017Q4	us-gaap	Liabilities Liabilities	2439320	USD
CY2016Q4	us-gaap	Liabilities Liabilities	480303	USD
CY2017Q4	us-gaap	Notes Payable Related Parties Noncurrent NotesPayableRelatedPartiesNoncurrent	0	USD
CY2016Q4	us-gaap	Notes Payable Related Parties Noncurrent NotesPayableRelatedPartiesNoncurrent	25000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	18498	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	221868	USD
CY2017Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	10800	USD
CY2016Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	2600	USD
CY2017Q4	us-gaap	Other Accrued Liabilities Noncurrent OtherAccruedLiabilitiesNoncurrent	3211	USD
CY2016Q4	us-gaap	Other Accrued Liabilities Noncurrent OtherAccruedLiabilitiesNoncurrent	1439	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	184649	USD
CY2016Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	100644	USD
CY2017	us-gaap	Revenues Revenues	4800	USD
CY2017	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	260085	USD
CY2017	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	898526	USD
CY2017	us-gaap	Operating Expenses OperatingExpenses	1174606	USD
CY2017	us-gaap	Operating Income Loss OperatingIncomeLoss	-1177806	USD
CY2017	us-gaap	Net Income Loss NetIncomeLoss	-2659108	USD
CY2017	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	106323582	shares
CY2017	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.03
CY2016	us-gaap	Revenues Revenues	0	USD
CY2016	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	85334	USD
CY2016	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	664984	USD
CY2016	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	9356	USD
CY2016	us-gaap	Operating Expenses OperatingExpenses	759674	USD
CY2016	us-gaap	Operating Income Loss OperatingIncomeLoss	-759674	USD
CY2016	us-gaap	Net Income Loss NetIncomeLoss	-766072	USD
CY2017	us-gaap	Share Based Compensation ShareBasedCompensation	144160	USD
CY2016Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	189064	USD
CY2017Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	142800	USD
CY2017Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	251748	USD
CY2016Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	0	USD
CY2017	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	171181	USD
CY2017	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	18932	USD
CY2017	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-27250	USD
CY2017	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-889621	USD
CY2017	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	USD
CY2017	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	USD
CY2017	celz	Proceeds From Subscription Receivable ProceedsFromSubscriptionReceivable	0	USD
CY2017	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	100000	USD
CY2017	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	8200	USD
CY2017	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	681450	USD
CY2017	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-208171	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	13697	USD
CY2017	us-gaap	Interest Paid Net InterestPaidNet	11100	USD
CY2017	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	USD
CY2016	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	22601	USD
CY2016	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	6318	USD
CY2016	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	280000	USD
CY2016	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-445232	USD
CY2016	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-10000	USD
CY2016	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	677000	USD
CY2016	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	221768	USD
CY2016	us-gaap	Interest Paid Net InterestPaidNet	0	USD
CY2016	celz	Proceeds From Subscription Receivable ProceedsFromSubscriptionReceivable	49500	USD
CY2016	us-gaap	Share Based Compensation ShareBasedCompensation	2565	USD
CY2016	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	10000	USD
CY2016	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	500000	USD
CY2016	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	2500	USD
CY2017Q4	celz	Working Capital Deficit WorkingCapitalDeficit	2416696	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	21144	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	21144	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	21144	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	21144	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	21144	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	78929	USD
CY2017Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	1800	USD
CY2017	celz	Employee Service Sharebased Compensation Nonvested Awards Expiration Period EmployeeServiceSharebasedCompensationNonvestedAwardsExpirationPeriod	2021
CY2017	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	-691368	USD
CY2016	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	-199179	USD
CY2017	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	-212729	USD
CY2016	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	-61286	USD
CY2017	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-904097	USD
CY2016	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-260465	USD
CY2017	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2016	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2017Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	950361	USD
CY2016Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	260464	USD
CY2017Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	1093161	USD
CY2017Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2016Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2017Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	1309190	USD
CY2016Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	0	USD
CY2017Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	915	USD
CY2016Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	0	USD
CY2016Q4	us-gaap	Other Notes Payable Current OtherNotesPayableCurrent	0	USD
CY2017Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4801	USD
CY2016Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	0	USD
CY2017Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2017Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q4	us-gaap	Other Notes Payable Current OtherNotesPayableCurrent	125000	USD
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	3000000000	shares
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	3000000000	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	115399226	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	105013750	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	114799226	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	105013750	shares
CY2017	us-gaap	Cost Of Revenue CostOfRevenue	8000	USD
CY2016	us-gaap	Cost Of Revenue CostOfRevenue	0	USD
CY2016	us-gaap	Gross Profit GrossProfit	0	USD
CY2017	us-gaap	Gross Profit GrossProfit	-3200	USD
CY2017	us-gaap	Interest Expense InterestExpense	377587	USD
CY2016	us-gaap	Interest Expense InterestExpense	6398	USD
CY2017	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1103715	USD
CY2016	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
CY2017	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1481302	USD
CY2016	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-6398	USD
CY2017	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><i><font style="FONT-SIZE: 10pt">Use of Estimates</font></i></strong><i><font style="FONT-SIZE: 10pt"> - </font></i> <font style="FONT-SIZE: 10pt">The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ from those estimates.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2016	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2565	USD
CY2017	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	31660	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	-157791	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	-2236173	USD
CY2017	celz	Stock Issued During Period Value New Issues With Convertible Notes Payable StockIssuedDuringPeriodValueNewIssuesWithConvertibleNotesPayable	22500	USD
CY2017Q4	us-gaap	Long Term Debt LongTermDebt	493250	USD
CY2017	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"></div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><i>Concentration Risks -</i></strong>  The Federal Deposit Insurance Corporation insures cash deposits in most general bank accounts for up to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">250,000</font> per institution.  The Company maintains its cash balances at one financial institution and at times the cash balances may exceed this amount.</div> </div> </div> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2017Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	100000	USD
CY2017	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	314066	USD
CY2017	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	112500	USD
CY2017	us-gaap	Stock Issued1 StockIssued1	0	USD
CY2016	us-gaap	Stock Issued1 StockIssued1	100000	USD
CY2017	us-gaap	Liabilities Assumed1 LiabilitiesAssumed1	0	USD
CY2017	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	322555	USD
CY2016	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0	USD
CY2017	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	-1103715	USD
CY2016	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	0	USD
CY2017	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	4801	USD
CY2016	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	0	USD
CY2017	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	90000	USD
CY2016	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	125000	USD
CY2017	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	483250	USD
CY2016	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	USD
CY2017Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	USD
CY2017	celz	Reimbursement Of Management Fees ReimbursementOfManagementFees	35000	USD
CY2017Q2	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	50000	USD
CY2016Q3	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	2000	USD
CY2017Q2	celz	Patents Payable PatentsPayable	100000	USD
CY2017Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	0	USD
CY2017Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	393250	USD
CY2016	celz	Stock Issued During Period To Related Party Value New Issues StockIssuedDuringPeriodToRelatedPartyValueNewIssues	30000	USD
CY2016	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	-44784	USD
CY2016	us-gaap	Stock Redeemed Or Called During Period Value StockRedeemedOrCalledDuringPeriodValue	0	USD
CY2017Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	1035069	USD
CY2017	us-gaap	Fair Value Assumptions Expected Dividend Rate FairValueAssumptionsExpectedDividendRate	0	pure
CY2017	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	561138	USD
CY2017	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	87600000	shares
CY2017Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	45000	USD
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	49500	USD
CY2016	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	470000	USD
CY2017	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	100000	USD
CY2016	us-gaap	Liabilities Assumed1 LiabilitiesAssumed1	43784	USD
CY2017	celz	Fair Value Of Warrants Issued In Private Placement FairValueOfWarrantsIssuedInPrivatePlacement	5546	USD
CY2016	celz	Fair Value Of Warrants Issued In Private Placement FairValueOfWarrantsIssuedInPrivatePlacement	32530	USD
CY2017	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired	100000	USD
CY2016	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired	1000	USD
CY2017	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	314066	USD
CY2016	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	0	USD
CY2017Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	1000000	shares
CY2017Q1	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	100000	USD
CY2017Q1	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	0.10
CY2017Q1	us-gaap	Warrants Not Settleable In Cash Fair Value Disclosure WarrantsNotSettleableInCashFairValueDisclosure	5546	USD
CY2017Q2	celz	Class Of Warrant Or Right Warrant Term ClassOfWarrantOrRightWarrantTerm	P5Y
CY2017Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.25
CY2017Q3	celz	Class Of Warrant Or Right Warrant Term ClassOfWarrantOrRightWarrantTerm	P5Y
CY2017Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.30
CY2017Q1	celz	Class Of Warrant Or Right Warrant Term ClassOfWarrantOrRightWarrantTerm	P2Y4M6D
CY2016Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	71400	USD
CY2017Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	557000	USD
CY2017Q4	celz	Management Reimbursement Agreementdescription ManagementReimbursementAgreementdescription	At the option of CMH, the reimbursable amounts set forth in the Agreement may be paid from time to time in shares of common stock of the Company at a price equal to a 30% discount to the lowest closing price during the 20 trading days prior to time the notice is given. The Agreement may be terminated by either party upon 30 days prior written notice.
CY2017	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Purchases FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases	1035069	USD
CY2017	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements	245956	USD
CY2017	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease	520077	USD
CY2016Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	0	USD
CY2017Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	1309190	USD
CY2017	celz	Increase In Principal Balance Due To Penalty Provision IncreaseInPrincipalBalanceDueToPenaltyProvision	25000	USD
CY2016	celz	Increase In Principal Balance Due To Penalty Provision IncreaseInPrincipalBalanceDueToPenaltyProvision	0	USD
CY2017Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	58000	USD
CY2017Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	52597	USD
CY2017Q2	celz	Redeemable Convertible Debenture Principal And Interest Percentage RedeemableConvertibleDebenturePrincipalAndInterestPercentage	1.4	pure

Files In Submission

Name	View Source	Status
0001144204-18-017967-index-headers.html	Edgar Link	pending
0001144204-18-017967-index.html	Edgar Link	pending
0001144204-18-017967.txt	Edgar Link	pending
0001144204-18-017967-xbrl.zip	Edgar Link	pending
celz-20171231.xml	Edgar Link	completed
celz-20171231.xsd	Edgar Link	pending
celz-20171231_cal.xml	Edgar Link	unprocessable
celz-20171231_def.xml	Edgar Link	unprocessable
celz-20171231_lab.xml	Edgar Link	unprocessable
celz-20171231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tv488947_10k.htm	Edgar Link	pending
tv488947_ex10-28.htm	Edgar Link	pending
tv488947_ex31-1.htm	Edgar Link	pending
tv488947_ex31-2.htm	Edgar Link	pending
tv488947_ex32-1.htm	Edgar Link	pending
tv488947_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CELZ
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. Stock $celz

2018 Q1 Form 10-K Financial Statement

#000114420418017967 Filed on March 29, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CELZ CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. Stock $celz

2018 Q1 Form 10-K Financial Statement

#000114420418017967 Filed on March 29, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CELZ
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. Stock $celz